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SUMMARY
How host genetics regulates neonatal intestinal adaptation
is unclear. Investigating a single immunoglobulin interleukin-1–related receptor (SIGIRR) mutation identiﬁed in an
infant with necrotizing enterocolitis reveals that signal
transducer and activator of transcription 3 (STAT3)–
microRNA–mediated repression of interleukin-1–related
associated kinase 1(IRAK1) protein is lost with SIGIRR
mutation. This results in deviant Toll-like receptor signaling
and loss of postnatal intestinal adaptation.

BACKGROUND & AIMS: Single immunoglobulin interleukin1–related receptor (SIGIRR) is a major inhibitor of Toll-like receptor
signaling. Our laboratory identiﬁed a novel SIGIRR stop mutation

(p.Y168X) in an infant who died of severe necrotizing enterocolitis
(NEC). Herein, we investigated the mechanisms by which SIGIRR
mutations induce Toll-like receptor hyper-responsiveness in the
neonatal gut, disrupting postnatal intestinal adaptation.
METHODS: Clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 was used to generate transgenic mice
encoding the SIGIRR p.Y168X mutation. Ileal lysates, mouse
intestinal epithelial cell (IEC) lysates, and intestinal sections
were used to assess inﬂammation, signal transducer and activator of transcription 3 (STAT3) phosphorylation, microRNA
(miRNA), and interleukin-1–related–associated kinase 1
(IRAK1) expression. Western blot, quantitative reversetranscription polymerase chain reaction(qRT-PCR), and luciferase assays were performed to investigate SIGIRR–STAT3
signaling in human intestinal epithelial cells (HIEC) expressing
wild-type or SIGIRR (p.Y168X) plasmids.
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RESULTS: SigirrTg mice showed increased intestinal inﬂammation and nuclear factor-kB activation concomitant with
decreased IEC expression of miR-146a and miR-155. Mechanistic studies in HIECs showed that although SIGIRR induced
STAT3-mediated expression of miR-146a and miR-155, the
p.Y168X mutation disrupted SIGIRR-mediated STAT3dependent miRNA expression. Chromatin immunoprecipitation and luciferase assays showed that SIGIRR activation of
STAT3-induced miRNA expression is dependent on IRAK1. Both
in HIECs and in the mouse intestine, decreased expression of
miR-146a observed with the p.Y168X mutation increased
expression of IRAK1, a protein whose down-regulation is
important for postnatal gut adaptation.
CONCLUSIONS: Our results uncover a novel pathway
(SIGIRR–STAT3–miRNA–IRAK1 repression) by which SIGIRR
regulates postnatal intestine adaptation, which is disrupted by
a SIGIRR mutation identiﬁed in human NEC. These data provide
new insights into how human genetic mutations in SIGIRR
identiﬁed in NEC result in loss of postnatal intestinal immune
tolerance. (Cell Mol Gastroenterol Hepatol 2022;13:425–440;
https://doi.org/10.1016/j.jcmgh.2021.09.009)
Keywords: SIGIRR; microRNA; STAT3; Intestinal Inﬂammation.
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reterm infants are at increased risk of necrotizing
enterocolitis (NEC), characterized pathologically by
intestinal necrosis and inﬂammation. NEC develops in 5%–
14% of preterm infants born before 30 weeks’ gestation and
has a mortality rate of 20%–35%.1 Although the pathogenesis of NEC remains unclear, genetic, nutritional, and
environmental risk factors that favor deviant interactions
between the intestinal mucosa and gut microbiota portend
NEC vulnerability.1–4 Animal models suggest that aberrant
activation of intestinal Toll-like receptor 4 (TLR4), a sensor
of lipopolysaccharide derived from gram-negative bacteria
is a central event in NEC pathogenesis, and TLR4-/- mice are
protected against experimental NEC.5,6 Studies on human
intestinal tissues derived from preterm infants with NEC
also have suggested that genes that mediate TLR signaling
such as TLR4, myeloid differentiation primary response 88
(MYD88), and downstream cytokines are increased in NEC,
while negative regulators of TLR signaling such as single
immunoglobulin interleukin-1–related receptor (SIGIRR)
and A20 have decreased expression in NEC.7 Whether a
native state of TLR4 hyper-responsiveness that favors
intolerance to colonizing bacteria in the developing intestine
exists, and the factors that prime TLR hypersensitivity,
remain unknown.8,9
After birth, the neonatal intestinal mucosa is exposed to
commensal and pathogenic microbial organisms recognized
by innate immune receptors, such as TLRs. TLRs contribute
to antimicrobial host defense and intestinal homeostasis,10
but aberrant activation of TLR signaling, notably TLR4,
has been implicated in mucosal injury and inﬂammation
underlying NEC and other diseases.5,8,9 TLR-related
signaling in intestinal epithelial cells (IECs) must be
tightly regulated to protect the neonatal gut from TLR hypersensitivity and inﬂammation induced by gut microbiota.

Down-regulation and apical to basal localization of TLR4
and postnatal decrease in the expression of the key TLR
canonical signaling kinase, interleukin-1–receptor–associated
kinases 1 (IRAK1), are some mechanisms facilitating postnatal intestinal tolerance. Enhanced expression of negative
regulators of TLR4 signaling also promote intestinal mucosal
tolerance to bacteria.7,11,12 SIGIRR, a major negative regulator
of TLR signaling, is an orphan receptor composed of an
extracellular domain, transmembrane domain, and intracellular Toll/interleukin-1 receptor (TIR) domain. SIGIRR inhibits TLR signaling by competitively binding to MYD88, the
major TLR adapter, through its TIR domain, and inhibiting
TLR–MYD88 signal transduction. SIGIRR has been implicated
in NEC pathogenesis. Our laboratory identiﬁed multiple
SIGIRR mutations in preterm NEC patients, and we have
posited that loss of functional SIGIRR variants may increase
the vulnerability of preterm infants to TLR-mediated
inﬂammation and NEC.3,13 Whether SIGIRR variants alter
postnatal intestinal tolerance and the mechanisms by which
SIGIRR genetic variants contribute to postnatal intestinal
adaptation remain unanswered. In this study, we developed a
novel Sigirr mutant mouse that recapitulates a truncating
mutation (p.Y168X) we previously identiﬁed in an infant with
NEC to investigate this question.13
TLR signaling also can be inhibited at the posttranscriptional level by microRNAs (miRNA), small noncoding RNA of approximately 2 nucleotides. Anti-inﬂammatory
miRNAs, such as miR-146a and miR-155, target TLR
pathway components required for signal transduction, and
are expressed abundantly in the intestinal epithelium.14,15
Sustained intestinal expression of miR-146a in the intestinal epithelium is essential for establishment of innate immune tolerance to colonizing bacteria.16 The mechanisms
that regulate miR-146a expression in neonatal intestine are
incompletely understood. Understanding regulation of antiinﬂammatory microRNA expression is directly relevant to
NEC pathogenesis because imbalances in expression of
proinﬂammatory vs anti-inﬂammatory miRNAs have been
reported in intestinal tissues obtained from preterm infants
with NEC.17,18 Based on knowledge described earlier, we
hypothesized that SIGIRR may regulate TLR sensitivity
and IRAK1 expression in neonatal intestinal epithelium

Abbreviations used in this paper: cDNA, complementary DNA; ChIP,
chromatin immunoprecipitation; DOL, day of life; FBS, fetal bovine
serum; HIEC, human intestinal epithelial cell; IEC, intestinal epithelial
cell; IL, interleukin; IL1R, interleukin-1 receptor; IRAK1, interleukin-1–
related–associated kinase 1; miRNA, microRNA; MYD88, myeloid differentiation primary response 88; NEC, necrotizing enterocolitis;
NF-kB, nuclear factor-kB; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; shRNA, short hairpin RNA; siRNA, small
interfering RNA; SIGIRR, single immunoglobulin interleukin-1–related
receptor; STAT3, signal transducer and activator of transcription 3;
TIR, Toll/interleukin-1 receptor; TLR, Toll-like receptor; CRISPR/Cas9,
(clustered regularly interspaced short palindromic repeats); ACTB,
actin beta.
Most current article

© 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA
Institute. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
2352-345X
https://doi.org/10.1016/j.jcmgh.2021.09.009

2022

through microRNA. Herein, we show that SIGIRR regulates
miR-146a expression through IRAK1-mediated signal
transducer and activator of transcription 3 (STAT3)-dependent
transcriptional activation both in cultured primary human
intestinal epithelial cells and in neonatal small intestine.

Results
SIGIRR Regulates Expression of microRNAs in
Primary Human IECs
To determine whether SIGIRR regulates the expression
of anti-inﬂammatory microRNAs, an RNA interference–based
approach was used. Three days after transfection of human
intestinal epithelial cells (HIECs) with SIGIRR-targeting small
interfering RNA (siRNA) (SIGIRR siRNA), SIGIRR abundance
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was reduced by approximately 60% compared with the
control (untransfected) group (Figure 1A). HIECs treated
with SIGIRR siRNA showed 50% decreased expression of
anti-inﬂammatory miR-146a and miR-155 than did control
siRNA-transfected cells, as detected by quantitative polymerase chain reaction (PCR) (Figure 1B). Because mir-215
has been shown to protect against lipopolysaccharideinduced inﬂammation in myoblast cells, and is decreased in
human NEC intestine,17,19 mir-215 expression level also was
examined. Similar to the other 2 microRNAs, mir-215
expression decreased in HIECs with SIGIRR knockdown
(Figure 1B). We next examined whether SIGIRR mediated
microRNA expression through nuclear factor-kB (NF-kB).
SIGIRR-silencing induced p65 (RELA proto-oncogene, NF-kB
subunit(RELA)) phosphorylation as anticipated in parallel

Figure 1. SIGIRR is required for anti-inﬂammatory microRNA expression in HIECs. (A) HIEC lysates of nontransfected(C,
control), transfected with Scramble siRNA and SIGIRR siRNA were analyzed by Western blot using the indicated antibodies,
with densitometry quantiﬁcation shown graphically. (B) microRNA expression was quantiﬁed by real-time PCR in HIECs
transfected with scramble or SIGIRR siRNA. (C) HIECs were transfected with pcDNA3–empty vector (EV), pcDNA3–SIGIRR,
and pcDNA3–SIGIRR p168X mutant, and the cell lysates were analyzed by Western blot using the indicated antibodies. The
densitometry quantiﬁcation is shown graphically. (D) microRNA expression was quantiﬁed by real-time PCR in HIECs with
indicated transfection. *P < .05, #P < .05, **P < .01, ***P < .005. ACTB, actin beta.
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with decreased miRNA expression (Figure 1A and B),
excluding its role in positive regulation of miRNAs. STAT3 is a
well-studied transcription factor antagonizing proinﬂammatory signals during innate immune response,20 and is
known to regulate expression of miRNAs in human hepatocellular carcinoma cells and T-helper 17 cells,21,22 so
expression of STAT3 and its phosphorylated form were
examined. We noted that serine phosphorylation of STAT3 at
residue 727 (STAT3Ser727), a major regulation site for STAT3
transcriptional activation, was reduced in SIGIRR-knockdown
HIECs, while the total STAT3 level remain unchanged
(Figure 1A).
To assess direct relevance of SIGIRR mutations identiﬁed in NEC infants on SIGIRR-dependent STAT3 phosphorylation and miRNA expression, we focused on the
SIGIRR stop mutation that truncates the intracellular TIR
domain at residue Y16813 (Figure 3F). STAT3Ser727 phosphorylation and anti-inﬂammatory microRNAs were
induced in HIECs transfected with wild-type SIGIRR
compared with HIECs expressing empty plasmid
(Figure 1C). SIGIRR p.Y168X mutant failed to promote
microRNA expression (Figure 1D), but repressed their
expression instead, indicating that the intracellular
domain of SIGIRR may be required for signal transduction
to activate STAT3Ser727 phosphorylation and antiinﬂammatory microRNAs expression. The 2.5- to 3.0-fold
increase in miRNA expression after SIGIRR transfection was
relatively modest, but was consistent. This potentially arose
from decreased efﬁciency of transient transfections, and
variation in timing of the peak change. These data indicate
that SIGIRR regulates baseline expression of antiinﬂammatory miRNA in association with STAT3 phosphorylation, and human SIGIRR mutations that truncate the TIR
domain abolish SIGIRR-dependent miRNA expression.

STAT3 Directly Binds to microRNA Promoters
and Activates Expression in a SIGIRRDependent Manner
The 2-kb promoter of miR-146a, miR-155, and mir-215
was predicted to possess multiple Stat3 binding sites by
JASPAR (http://jaspar.genereg.net). The binding of STAT3
on promoters of microRNA was evident by chromatin
immunoprecipitation (ChIP) assay using Stat3-speciﬁc
antibody followed by qPCR with primers targeting microRNA promoter regions predicted to have the highest binding
score (Figure 2A). We next examined the inﬂuence of SIGIRR
on the binding afﬁnity of STAT3 microRNAs in HIECs
transfected with SIGIRR siRNA. As shown, STAT3 binding
to microRNA promoter was abolished in SIGIRR siRNAtransfected HIECs compared with control siRNA-transfected
HIECs (Figure 2B). Expression of SIGIRR p.Y168X mutant
also decreased the binding afﬁnity of Stat3 to the microRNA
promoter (Figure 2C).
To determine whether STAT3 functions as a transcriptional activator for microRNAs, we generated a luciferase
reporter by inserting the 2-kb miR-146a promoter before the
luciferase coding fragment. Co-transfection with a wild-type
STAT3 plasmid strongly activated miR-146a promoter

activity. Strikingly, the phosphorylation defective S727A
mutant of STAT3 only displayed approximately 50% transcriptional activation compared with wild-type STAT3
(Figure 2E). To deﬁne their role in miRNA promoter activation, STAT3 binding sites at miR-146a promoter were
mutated by site-directed PCR mutagenesis. Because of multiple potential STAT3 binding sites, we chose to mutate the 2
sites showing the highest binding afﬁnity scores. Reporter
activation by wild-type STAT3 was attenuated nonsigniﬁcantly when individual STAT3 binding sites at the miR-146a
promoter were deleted, and signiﬁcantly when both sites
were deleted (Figure 2F). Importantly, SIGIRR was unable to
activate miR-146a promoter activity when both STAT3 promoter binding sites on miR-146a were deleted (Figure 2F).
STAT3 regulation of miRNA expression was tested in HIECs
by blocking STAT3 activation using a small-molecule inhibitor
named Stattic, which selectively inhibits activation, dimerization, and nuclear translocation of STAT3.23 MicroRNA
expression was strikingly decreased in a dose-dependent
manner after 16 hours of STAT3 inhibitor treatment
(Figure 2G). Alternatively, knocking-down STAT3 using short
hairpin RNA (shRNA)-based RNA interference reduced
miRNA expression in HIECs (Figure 2H and I). Taken together,
these results indicate that SIGIRR regulates STAT3-dependent
anti-inﬂammatory microRNA promoter activity and expression at baseline without exogenous ligand stimulation.

IRAK1-Dependent Phosphorylation of Stat3 Is
Required for miRNA Expression in HIECs
To examine how SIGIRR mediates STAT3 phosphorylation, we targeted IRAK1, positing that the TIR domain
of SIGIRR can interact with MYD88 and IRAK1 to mediate
signal transduction. Co-immunoprecipitation studies
showed that SIGIRR co-immunoprecipitated with IRAK1
and MYD88 while normal IgG failed to yield either protein, suggesting that SIGIRR forms a complex with IRAK1
and MYD88 independent of exogenous TLR ligand stimulation (Figure 3A and G). Further corroboration was
provided with studies showing that overexpression of
SIGIRR wild-type protein enhanced binding with IRAK1
and MYD88. The SIGIRR mutation identiﬁed in NEC,
which lacks the TIR domain, interfered with wild-type
SIGIRR binding to IRAK1 and MYD88 (Figure 3B), indicating it may function as a dominant-negative mutant.
IRAK1 dependency of STAT3 Ser727 phosphorylation
was examined using a selective inhibitor of IRAK1/4 kinase activity. STAT3 Ser727 phosphorylation was inhibited
16 hours after treatment with the IRAK1/4 inhibitor in a
dose-dependent manner (Figure 3C). In parallel with
phosphorylation,
antidecreased
STAT3Ser727
inﬂammatory microRNA expression decreased with escalating doses of IRAK1 inhibitor (Figure 3D). ChIP assays
showed that IRAK1 inhibitor treatment prevented STAT3
binding to the microRNA promoter, which resulted in less
transcriptional activation of microRNAs (Figure 3E).
Taken together, our results suggest that SIGIRR binds to
IRAK1, and directs IRAK1-dependent, STAT3-mediated
transcriptional activation of miRNA expression.
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Figure 2. STAT3 activates microRNA expression in a SIGIRR-dependent manner. (A) Quantitative-ChIP assay was performed using anti-STAT3 antibody to analyze the recruitment of STAT3 on promoters of miR-146a, miR-155, and mir-215 in
HIECs. Values were quantiﬁed against IgG controls. (B and C) ChIP quantitative PCR values of STAT3 recruitment on
microRNA promoters in HIECs with indicated transfection. (D) Promoter reporter activity assay was performed in HEK293T
cells transfected with luciferase reporter plasmid pGL4.1 empty vector or pGL4.1 containing human miR-146a promoter,
and thymidine kinase promoter–Renilla luciferase reporter plasmid (pRL-TK), serving as a internal transfection control.
Luciferase assay was performed with cell lysates using the Dual-Luciferase Reporter Assay System(Promega, Madison, WI).
(E) Promoter reporter activity assays were performed in HEK293T cells co-transfected with pGL4.1–miR-146a promoter and
indicated STAT3 plasmids. (F) Promoter reporter activity assays were performed in HEK293T cells using PGL4.1–miR-146a
promoter with nucleotide mutations at STAT3 binding sites. HEK293T were co-transfected with wild-type miR-146a promoter luciferase reporter or mutant reporter. The relative luciferase activities obtained from 5 to 6 independent experiments
are shown as means ± SD. (G) microRNA expression was quantiﬁed by real-time PCR in HIECs treated with STAT3 inhibitor,
STATTIC, for 24 hours at the indicated concentration. (H) microRNA expression was quantiﬁed by real-time PCR in HIECs
transduced with control shRNA or Stat3 shRNA. *P < .05, ***P < .005. ACTB, actin beta; DM, mutations at STAT3 binding
site 1 and site 2; EV, pcDNA3–empty vector; M1, mutations at STAT3 binding site 1; SCR, scrambled; SIGIRR,
pcDNA3–SIGIRR; 168X, pcDNA3–SIGIRR P168X.

SIGIRR-Mediated Inhibition of TLR4 Signaling Is
Dependent on Stat3–miRNA Activation
SIGIRR is known to mediate inhibition of TLR signaling
by disrupting TIR–TIR interactions between TLR receptors
and adapter MYD88. We probed the functional relevance of
the SIGIRR–STAT3–miRNA axis to suppression of proinﬂammatory TLR signaling in HIECs. To investigate this, we

used a lentiviral shRNA knock strategy to generate HIECs
(HIECStat3-) with more than 60% stable knockdown of
STAT3 (Figure 2H). Plasmid-mediated expression of SIGIRR
in HIECStat3- did not suppress ﬂagellin (TLR5 agonist)induced interleukin (IL)1b and C-X-C motif chemokine
ligand 1 expression at 16 hours to the extent observed in
HIECs (HIECStat3þ) transduced with scrambled shRNA
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lentivirus-vector (Figure 4A). To further prove miRNAs are
involved in SIGIRR-mediated suppression of TLR5-induced
inﬂammation, we used miR-146a inhibitor to block miR-

146a function in HIECs and found that SIGIRR was not
able to suppress ﬂagellin-induced inﬂammatory cytokine
expression (Figure 4B). Besides blocking SIGIRR function

2022

using miR-146a inhibitor, we also used miR-146a mimic to
rescue function of the p.Y168X variant in TLR signaling
suppression. Strikingly, we observed that the miR-146a
mimic rescued SIGIRR function to suppress ﬂagellininduced cytokine expression in HIECs (Figure 4C).
Besides the SIGIRR p.Y168X stop mutant, we also identiﬁed other genetic variants associated with human NEC previously.13 The SIGIRR p.P115R variant was predicted (The
Phyre2 web portal , http://www.sbg.bio.ic.ac.uk/phyre2/
html/page.cgi?id¼index ) to alter the structure of the ﬁrst
a-helix of the TIR intracellular domain (Figure 3F and H). We
therefore evaluated the effect of the p.P115R SIGIRR variant
identiﬁed in NEC on regulating anti-inﬂammatory miRNA
expression. Compared with wild-type SIGIRR, the p.P115R
variant had reduced ability to induce STAT3 (Ser727) phosphorylation or microRNA expression, and did not suppress
ﬂagellin-induced inﬂammation (Figure 4D and E). These data
suggest that SIGIRR human mutations that disrupt function of
the intracellular TIR domain have decreased ability to induce
STAT3-dependent miRNA expression.

SIGIRR Mutant Mice Encoding a Truncated TIR
Domain (p.P174X) Show Spontaneous Neonatal
Intestinal Inﬂammation With Decreased
microRNA Expression
Loss of the SIGIRR TIR domain ensuing from the p.Y168X
mutation identiﬁed in human NEC resulted in loss of STAT3mediated microRNA expression and exaggerated TLR5
responsiveness in HIECs. To investigate the in vivo ramiﬁcations of this ﬁnding we used clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology
to generate a novel transgenic mouse encoding a premature
stop codon at the Sigirr locus to mimic the human truncating mutation p.Y168X (Figure 5A). The mutation in mice
(SigirrTg) genocopies the human mutation by truncating the
mouse intracellular TIR domain at amino acid residue 174
(Figure 5A). The truncating mutation resulted in a protein
that was 18 kilodaltons, compared with full-length SIGIRR,
which was 54 kilodaltons (Figure 5B). Immunoﬂuorescence
studies showed that SIGIRR was expressed along the
crypt–villus axis, both at the apical and basal aspects of
mouse IECs. Interestingly, the SIGIRR mutant resulted in
decreased SIGIRR protein expression in both crypt and villi
(Figure 5C), which also was conﬁrmed by quantitative RNA
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analysis of the SIGIRR transcript in IEC lysates (Figure 6C).
This suggests that truncation results in nonsense-mediated
decay, resulting in decreased levels of truncated SIGIRR
RNA and protein. Strikingly, we noted a dose-dependent
increase in spontaneous intestinal inﬂammation in the terminal ileum, even with heterozygous neonatal pups showing
increased expression of cytokines, such as Ifnb1 and Tnfa,
compared with littermate wild types (Figure 5D). Intercellular adhesion molecule expression as well as markers of
canonical TLR pathway signaling such as p65 (RELA)
phosphorylation were induced in the terminal ileum of
heterozygous and homozygous SigirrTg mice on day of life
(DOL)-8 (Figure 5B). These data suggest that in mice
encoding a SIGIRR TIR domain-truncating mutation, there is
TLR hypersensitivity with increased ileal intestinal cytokine
expression and TLR canonical pathway activation.

SigirrTg Mice Have Decreased Intestinal
Expression of microRNAs and Phospho-STAT3
but Have Increased Expression of IRAK1
We next investigated the relationship between SIGIRR
and microRNA expression in the developing intestine. Loss
of SIGIRR expression was accompanied by a concomitant
dose-dependent decrease in phosphorylated STAT3 Ser727
expression (Figure 6A). IECs were isolated from neonatal
terminal small intestine and epithelial identity conﬁrmed by
immunoﬂuorescence staining for epithelial cell adhesion
molecule (EpCAM) and E-cadherin (Figure 6B). Heterozygous and homozygous SigirrTg IECs showed reduced
expression of all miRNAs on DOL-11 (Figure 6D). miRNA
expression also decreased in lysates obtained from the
terminal ileum of SigirrTg mice on DOL-8 and DOL-11
(Figure 5E). These data show that in SigirrTg mice,
decreased expression of anti-inﬂammatory miR-146a and
miR-155 is associated with spontaneous TLR pathway
activation. Other investigators have shown that miR146a–mediated IRAK1 suppression in IECs is essential for
immune TLR pathway tolerance to gut bacteria in neonatal
intestine.16,24 We therefore examined whether decreased
miR-146a and TLR sensitivity noted in SigirrTg mice correlates with persistence of IRAK1 protein in mouse IECs.
IRAK1 (a miR-146a target) protein expression levels were
increased in IECs as shown in IEC lysates on DOL-11 in
heterozygote and homozygous SigirrTg mice and by immu-

Figure 3. (See previous page). STAT3 phosphorylated by IRAK1 regulates microRNA expression. (A) SIGIRR interacts
speciﬁcally with IRAK1 and MYD88, but not TLRs in HIECs at baseline. HIEC lysates were immunoprecipitated by SIGIRR
antibody, then immunoprecipitated complexes were immunoblotted with the indicated antibodies. (B) HIECs were transfected
with pcDNA3–empty vector (EV), pcDNA3–SIGIRR (SIGIRR), and pcDNA3–SIGIRR plus pcDNA3-SIGIRR p168X mutant,
immunoprecipitation (IP) was performed using SIGIRR antibody and analyzed by Western blot with the indicated antibodies. (C
and D) HIECs were treated with the IRAK1/4 inhibitor at the escalated concentrations for 24 hours, then were lysed for Western
blot (WB) and real-time PCR analysis of microRNA expression. (E) ChIP quantitative PCR values of STAT3 recruitment on
microRNA promoters in HIECs treated with IRAK1/4 inhibitor for 16 hours. (F–H) SIGIRR protein models for study. (F) The farleft structure shows the full mature SIGIRR protein structure (amino acids 1–410, Q6IA17; UniProt) within a lipid membrane
(cyan), with labeled domains and portions of the cell. The next model shows the full protein without the membrane and labeling
in red amino acid P115 and Y168. The next 2 models show SIGIRR p.P115R and p.Y168X. (G) Molecular surface plot of the
intracellular Toll-interleukin receptor domain (gray) for the full SIGIRR or SIGIRR p.Y168X interacting with MYD88 (magenta).
(H) Predicted effect of the SIGIRR p.P115R mutant on the ﬁrst a helix of the intracellular TIR domain. The predicted change of
protein structure in SIGIRR p.P115R mutant is marked by red boxes. *P < .05. ACTB, actin beta; C , control.
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Figure 4. SIGIRR suppresses TLR-induced inﬂammation partially via anti-inﬂammatory microRNAs. (A) SIGIRR inhibits
ﬂagellin-induced proinﬂammatory cytokine expression through STAT3. HIECs stably expressing lentiviral Stat3 shRNA or
scramble shRNA (SCR) were transfected with pcDNA3–empty vector (EV) or pcDNA3-SIGIRR for 48 hours, then treated with
ﬂagellin at 50 ng/mL for 8 hours. Proinﬂammatory cytokines and microRNA expression were quantiﬁed by real-time PCR. (B)
miR-146a inhibitor restores IL1b and C-X-C motif chemokine ligand 1 (CXCL1) expression suppressed by SIGIRR. HIECs were
treated with ﬂagellin for 8 hours after 48 hours of transfection of pcDNA3-SIGIRR and miR-146a inhibitor or scramble control.
IL1b and CXCL1 expression were analyzed by real-time PCR. (C) HIECs were transfected with plasmids and miR-146a mimic
or scramble control as indicated for 48 hours, then treated with ﬂagellin for 6 hours at 100 ng/mL. IL1b and CXCL1 expression
were analyzed by real-time PCR. (D) HIECs were transfected with pcDNA3–EV, pcDNA3–SIGIRR, and pcDNA3–SIGIRR
p.P115R mutant, and cell lysates were analyzed by Western blot using the indicated antibodies. Densitometry quantiﬁcation is
shown graphically. (E) microRNA expression was quantiﬁed by real-time PCR in HIECs with indicated transfection. *P < .05,
**P < .01, ACTB, actin beta.

noﬂuorescence (Figure 6E and F). STAT3Ser727 phosphorylation in IECs was decreased in SigirrTg mice compared with
littermate controls, while total STAT3 expression levels
were comparable (Figure 6E). These data indicate that
SigirrTg mice have decreased IEC expression of antiinﬂammatory microRNAs in association with decreased
STAT3 phosphorylation and increased IRAK1 expression.

IRAK1–STAT3 Mediated microRNA Expression in
Mouse Intestinal Epithelium
Because microRNA expression is regulated by IRAK1–
STAT3 signaling in human IECs in vitro, we examined

conservation of this signaling pathway in developing intestine using wild-type mice. DOL-6 wild-type pups were
orally administered IRAK1 inhibitor at 20 mg/kg or vehicle
once a day for 3 days. Stat3 Ser727 phosphorylation in
IECs treated with IRAK inhibitor was decreased signiﬁcantly compared with vehicle control. miR-146a, miR-155,
and mir-215 levels were suppressed owing to IRAK1 inhibition (Figure 7A). Reduced STAT3 Ser727 phosphorylation was observed in IRAK1-inhibitor–treated IECs,
indicating that IRAK1 phosphorylated STAT3 and regulated
microRNAs expression in vivo (Figure 7B). Similarly, inhibition of STAT3 with the inhibitor decreased miRNA expression
and induced proinﬂammatory cytokine expression in
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Figure 5. Spontaneous inﬂammation with low-level microRNA expression in small intestine of neonatal SigirrTg mutant
mice. (A) Genotyping of SigrrTg mice and sequencing of Sigirr cDNA from mutant mice was performed to conﬁrm the deletion
of TIR domain. Tgþ/þ represents the wild type, Tgþ/- and Tg-/- represent mice heterozygous or homozygous for the Sigirr
p.P174X mutant, respectively. The premature stop codon in SIGIRR gene is marked by red box. (B) Whole lysate protein
obtained from terminal ileum of littermate DOL-11 SigrrTg mutant mice was immunoblotted for indicated antibodies, with
densitometry quantiﬁcation shown graphically. (C) Immunoﬂuorescent confocal images of DOL-11 mouse terminal ileum
stained with SIGIRR antibody. (D) Proinﬂammatory cytokines were quantiﬁed by real-time PCR in terminal ileum of DOL-8 and
DOL-11 SigirrTg mice. (E) microRNA expression in terminal ileum of DOL-8 and DOL-11 SigirrTg mice was quantiﬁed by realtime PCR. *P < .05, **P < .01, ***P < .005. ACTB, actin beta; DAPI, 40 ,6-diamidino-2-phenylindole; ICAM1, intercellular
adhesion molecule 1; TNF, tumor necrosis factor.

mouse ileum (Figure 7C and D) epithelium. These results
also were observed in ileal IECs from neonatal mice treated
with the STAT3 inhibitor, Stattic. Together, these data suggest that the SIGIRR–IRAK1–Stat3 axis regulates antiinﬂammatory microRNA expression in the neonatal intestinal epithelium.

Discussion
The neonatal intestinal mucosa has to rapidly adapt to a
new environment containing commensal and pathogenic

bacteria after birth. As a major negative regulator, SIGIRR
canonically inhibits TLR and IL1 receptor (IL1R)-mediated
inﬂammation through competitively binding MYD88 and
inhibiting TIR homology domain interactions between TLR/
IL1R and MYD88 immediately after ligand stimulation.25,26
Whether SIGIRR regulates TLR signaling through posttranslational inhibition of key TLR signaling pathway effectors and the mechanisms involved remain unknown.
Our results identiﬁed a novel inhibitory SIGIRR signaling
cascade via STAT3–miRNA–146a that suppresses IRAK1, a
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Figure 6. Decreased intestinal expression of microRNAs and increased TLR signaling molecules in SigirrTg mice. (A)
Immunoﬂuorescent confocal images of DOL-11 mouse terminal ileum stained with phospho-STAT3 (Ser727) antibody. (B)
Immunoﬂuorescent confocal images of isolated IECs from DOL-11 mouse terminal ileum stained with epithelial cell markers.
(C) Sigirr mRNA expression in isolated IECs. (D) microRNA expression in IECs isolated from terminal ileum of DOL-12 SigirrTg
mice was quantiﬁed by real-time PCR. (E) Mouse IEC lysates from littermate SigirrTg mice were analyzed by immunoblotting
with indicated antibodies, with densitometry quantiﬁcation shown graphically. (F) Immunoﬂuorescent confocal images of DOL11 mouse terminal ileum stained with IRAK1 antibody. *P < .05, **P < .01, ***P < .005, ****P< .001. ACTB, actin beta; DAPI, 40 ,6diamidino-2-phenylindole;
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Figure 7. Decreased intestinal expression of microRNAs and increased inﬂammation in wild-type neonatal mice
treated with IRAK and STAT3 inhibitor. (A) microRNA expression in mouse IECs from vehicle or IRAK inhibitor–treated mice
were quantiﬁed by real-time PCR. DOL-6 wild-type mice were orally administered IRAK inhibitor at 20 mg/kg of body weight
once per day for 3 days, then killed for IEC isolation and analysis. (B) Mouse IEC lysates were analyzed by immunoblotting with
the indicated antibodies. (C and D) Real-time PCR analysis of expression of microRNA and proinﬂammatory cytokines in IECs
isolated from wild-type mice with 3 days intraperitoneal injection of STATTIC at 2.5 mg/kg of body weight daily from DOL-7. *P
< .05, **P < .01. ACTB, actin beta.

known mediator of postnatal intestinal tolerance. Using
in vitro approaches in HIECs and a novel mouse that encodes a mutation we discovered in human NEC, we show
that SIGIRR regulates expression of anti-inﬂammatory
microRNAs through IRAK1-dependent, STAT3-mediated
transcriptional activation. SIGIRR-mediated miR-146a and
miR-155 expression in the neonatal gut inhibits IRAK1
expression, and loss of the SIGIRR TIR domain seen with the
SIGIRR p.P174X mutation results in TLR hyper-responsiveness
and spontaneous inﬂammation in neonatal intestine. These
data provide new insights into the acquirement of postnatal
intestinal TLR tolerance.
MiRNAs are key regulators of inﬂammatory responses
and immune regulation.27,28 MiR-146a is one of the ﬁrst
anti-inﬂammatory miRNAs identiﬁed to be involved in
innate immune responses.29 After birth, miR-146a expression is greatly induced and maintained at a high level during
the neonatal stage, and miR-146a–mediated IRAK1 suppression is critical for acquirement of innate immune
tolerance to colonizing bacterial in the neonatal intestine.16
However, the mechanism by which miR-146a expression is
induced and maintained in the neonatal intestinal epithelium still is unclear. Our data show decreased miR-146a in

SIGIRR-deﬁcient primary human IECs and in SIGIRR mutant
mouse neonatal intestine epithelium, indicating that SIGIRR
plays a major role in the regulation of miR-146a expression
in the neonatal intestinal epithelium. Similar to miR-146a,
miR-155 is another mitigator of inﬂammatory response that
targets MYD88, the mediator of TLR and IL1R signaling.28
miR-215 is emerging as an anti-inﬂammatory microRNA.19
MiR-155 and mir-215 are greatly decreased in the intestines of NEC patients,17,18 and we also observed that these
2 microRNAs are decreased in HIECs with the p.Y168X mutation, and in the small intestine IECs of mice encoding a
truncating SIGIRR mutation (p.P174X) that phenocopies the
human mutation. These data suggest that miR-155 and
mir-215 may be potential targets for the prevention and
treatment of hyperactive TLR-induced intestinal injury in
neonates. Although we focused on mir-146a, mir-155, and
mir-215, whether other microRNAs, such as let-7 and mir21,14 which inhibit TLR signaling, were altered by SIGIRR
loss of function needs to be investigated in the future.
STAT3 activation through IL6 or IL22 in IECs is a major
inhibitor of the intestinal inﬂammation through several
mechanisms including IL10 secretion.30,31 However, the role
of STAT3-dependent miRNA in repressing TLR signaling in
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the neonatal intestine, and its induction by SIGIRR, is poorly
understood. Here, we identiﬁed that the SIGIRR TIR domain
activates STAT3 through phosphorylation and mediates
STAT3-dependent anti-inﬂammatory microRNA expression
in neonatal intestinal epithelium. STAT3 is known to regulate miR-146a expression in hepatocellular carcinoma cells
and miR-155 in T-helper 17 cells.21,22 Given the role of miR146a and miR-155 in innate immune response,28 we propose that STAT3-regulated microRNA expression in IECs is
important for containing intestinal TLR signaling in
response to colonizing bacteria. This aids neonatal intestinal
immune tolerance, which is lost in mice genocopying a NECrelated human SIGIRR mutation. Our results show that
SIGIRR-dependent STAT3 activation results in its binding to
the promoter of anti-inﬂammatory microRNAs and inducing
their expression in intestine epithelial cells. Dysregulated
STAT3 function reduced expression of anti-inﬂammatory
microRNAs both in HIECs and mouse intestine, resulting
in failure of SIGIRR to suppress ﬂagellin-induced inﬂammation in HIECs and increased proinﬂammatory cytokine
expression in the mouse intestine. More importantly,
administration of miR-146a mimic rescued loss of function
related to the p.Y168X mutant in relation to TLR5-induced
inﬂammation. These results show a new mechanism by
which SIGIRR inhibits TLR canonical signaling through
STAT3-mediated miRNA expression, not only through the
conventional MYD88–NF-kB pathway. The embryonic
lethality of Stat3-/- mice precluded us from probing its direct
role in neonatal intestinal miRNA expression, although use
of an inhibitor supports our conclusions. Other members of
the STAT family are reported to be involved in regulation of
intestinal inﬂammation.32,33 Whether other STAT family
members are regulated by SIGIRR is an interesting topic for
future studies.
We discovered that IRAK1 is the SIGIRR downstream
kinase, which phosphorylates STAT3 at Ser727 in intestinal
epithelial cells. Our data are consistent with previous work
that has shown that IRAK1 can phosphorylate STAT3 at
Ser727 in splenocytes.34 The functional impact of IRAKmediated STAT3 Ser727 phosphorylation is demonstrated
by our data showing decreased miRNA expression in HIECs
and mouse IECs after IRAK inhibition despite the presence
of SIGIRR. During TLR-/IL1R-mediated innate immune
response, TLR or IL1R bind to MYD88 through their cytoplasmic TIR domains, forming a Myddosome complex along
with IRAK4 and IRAK1, resulting in activation of downstream signaling.35–37 Previously, Lotz et al24 showed that
postnatal acquirement of neonatal intestinal tolerance in
mice is related to decreases in IRAK1 protein, although
IRAK1 mRNA levels remained stable, suggesting posttranslational modiﬁcation. Subsequently, Chassin et al16
showed that miR-146a suppressed IRAK1 translation,
although their results suggested that low-level IRAK1 is
critical for maintaining miR-146a expression in the presence
of intraepithelial endotoxin. Our results showing that
SIGIRR represses IRAK1 protein and low levels of IRAK1
expression is adequate for SIGIRR-dependent, STAT3mediated miR-146a expression is consistent with Chassin
et al.16 Our co-immunoprecipitation data suggest that

SIGIRR can bind MYD88 at baseline via TIR domain assembly and may constitutively activate IRAK1 to phosphorylate STAT3 for maintaining microRNA expression even
without ligand stimulation. Impairing SIGIRR expression or
function by siRNA or TIR domain truncation mutant,
respectively, decreased STAT3 phosphorylation both in vitro
and in vivo, indicating that constitutive SIGIRR–MYD88
complex can activate IRAK1 kinase activity and contribute to
anti-inﬂammatory microRNA expression, critical for silencing
TLR signaling.
Postnatal acquirement of neonatal intestinal tolerance to
bacteria through tamponade of TLR4 signaling is important
for the prevention of NEC. Several mechanisms including
induction of miR-146a–mediated IRAK1 suppression and
induction of inhibitor of nuclear factor kappa B (IkB), which
sequesters NF-kB in the cytoplasm, are important.16,24,38
How miR-146a is induced in the neonatal intestine, facilitating IRAK1 suppression and TLR4 insensitivity, is unknown. To better understand SIGIRR regulation of neonatal
intestinal adaptation, we used CRISPR-Cas9 genome editing
to generate SigirrTg mice with a p.P174X mutation, which
truncates the TIR domain, mimicking the p.Y168X mutation
identiﬁed in human NEC.13 Combining loss-of-function/
gain-of-function of experiments in human fetal IECs with
studies in SigirrTg mice, we identiﬁed a novel mechanism
(SIGIRR–STAT3–miR-146a) in the neonatal intestine by
which SIGIRR represses IRAK1 and facilitates neonatal immune tolerance. Loss of this mechanism in SigirrTg mice
resulted in a dose-dependent increase in neonatal intestinal
inﬂammation at baseline. We believe our results provide
new insights into how mutations in SIGIRR, a potential locus
for NEC susceptibility in premature infants, create a milieu
of intestinal TLR hypersensitivity that might portend
neonatal gut injury phenotypes such as NEC. Future studies
will examine how mutations in SIGIRR and other potential
NEC susceptibility genes interact with the microbiome to
prime TLR sensitivity and program NEC vulnerability.3,39

Materials and Methods
Ethical Approval
Care of mice before and during experimental procedures
was conducted in accordance with the policies at the University of Missouri–Kansas City Laboratory Animal
Resource Center and the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
Protocols had prior approval from the University of
Missouri–Kansas City Institutional Animal Care and Use
Committee. Investigators understand the ethical principles
and the work described here complies with the animal
ethics checklist published in Cellular and Molecular Gastroenterology and Hepatology.

Generation of New Mice
Sigirr p.P174X mutant mice were generated by pronuclear injection of a CRISPR plasmid expressing Cas9 and
single-guide RNA into 1-cell C57BL/6 embryos. Founder
animals were genotyped and conﬁrmed by Sanger
sequencing to identify a founder animal harboring a 32-bp
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deletion, which generates a premature stop at amino acid
174. This mutant founder was back-crossed to the parental
strain to establish a breeding colony. All subsequent litters
were genotyped using the following primers: forward: 50 CTCTTTAACTGGCCCTGCTG-30 ; reverse: 50 -CAGGGAACAGAGTAGGGACC-30 .

Mouse Inhibitor Studies
For inhibitor treatments, DOL-6 C57BL/6J (B6) pups
were orally administered the IRAK inhibitor (cat. no. 5665;
Tocris, Minneapolis, MN) at 20 mg/kg for 3 days. For STAT3
inhibition, DOL-6 pups were injected intraperitoneally with
STAT3 inhibitor, Stattic (cat. no. sc-202818; Santa Cruz
Biotechnology, Santa Cruz, CA) at 2.5 mg/kg for 3 days.

Cell Culture
HIEC-6 (CRL-3266; American Type Culture Collection,
Manassas, VA) cells were grown in OptiMEM 1 Reduced
Serum Medium supplemented with 4% fetal bovine serum
(FBS), 20 mmol/L HEPES, 10 mmol/L GlutaMAX(ThermoFisher, Waltham, MA), and 10 ng/mL epidermal growth
factor in an atmosphere containing 5% CO2. Transfection
was performed using Lipofectamine 3000 (ThermoFisher)
according to the manufacturer’s protocol. Human embryonic
kidney HEK293T cells were cultured in Dulbecco’s modiﬁed
Eagle medium containing 10% FBS and antibiotic–antimycotic
(ThermoFisher). HIECs transduced by lentiviral particle
expressing Stat3 shRNA or control shRNA were passaged 2
times to eliminate the effect of lentivirus. HIECs were transfected with pcDNA3 vectors(Invitrogen, Waltham, MA) carrying wild-type SIGIRR or p168X mutant3 using
Lipofectamine 3000 according to the manufacturer’s protocol.
Three days after transfection, HIECs were lysed for mRNA and
protein expression analysis. For RNA interference, the speciﬁc
siRNA duplexes targeting human SIGIRR (sc-61547),
ﬂuorescein-conjugated control siRNA (sc-36869), transfection
reagent (sc-29528), and reduced-serum transfection medium
(sc-36868) were purchased from Santa Cruz Biotechnology.
When the cell conﬂuence reached 60%–80%, the cells were
washed with 1 phosphate-buffered saline (PBS) and transiently transfected with transfection complexes prepared according to the manufacturer’s instructions. At 48 or 72 hours
after transfection, silencing of SIGIRR at mRNA and protein
levels was checked by real-time PCR and Western blot,
respectively.

Isolation of Mouse Small Intestine Epithelial Cells
Mouse small intestine epithelial cells were isolated as
previously reported.40 Brieﬂy, 5 cm terminal ileum was
ﬂushed with cold PBS, opened longitudinally, and cut into 1cm pieces, followed by incubation in 5 mL Hank’s balanced
salt solution (Ca2þ Mg2þ free) with 2% FBS, 5 mmol/L
EDTA, and 1 mmol/L dithiothreitol in a 37 C shaker for 30
minutes. Cells were collected by passing supernatant
through a 100-mm cell strainer, and spinning at 300  g for
5 minutes. Isolated cells were conﬁrmed positive for epithelial
cells markers E-cadherin and epithelial cell adhesion molecule
(EpCAM) by immunoﬂuorescence.
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ChIP
The ChIP experiment was performed as previously
described.41 Brieﬂy, the HIECs were ﬁxed with 1% formaldehyde for 10 minutes. The Pierce Magnetic ChIP Kit and
ChIP grade Stat3 antibody (#4904; Cell Signaling, Danvers,
MA) were used according to the manufacturer’s instructions. ChIP products were analyzed by quantitative
real-time PCR. The sequences of primers were designed to
target Stat3 binding sites at microRNA promoters
according to the prediction of JASPAR 2018 (http://jaspar.
genereg.net/) and as listed: miR-155 forward:
5’-AAAGTTCCAGATCAAGGTCCTG-3’; miR-155 reverse: 5’AGAGACACCAGAATTCCCTTTC-3’;
miR-146a
forward:
5’-TCCAAGCATCCACTTTCCTG-3’; miR-146a reverse: 5’GTACATTATCCCGTTCCAGTCAG-3’;
mir-215
forward:
5’-TGGAACGCAGACCTTACAAG-3’; and mir-215 reverse: 5’AGTGGGATATAACAGGGATTTCAG-3’.

Luciferase Assay
The 2-kb promoter of miR-146a was PCR-ampliﬁed from
the human complementary DNA (cDNA) library and cloned
into pGL4.10 (Promega, Madison, WI). To gain high transfection efﬁciency, HEK293T cells were used for luciferase
assays. HEK293T cells were co-transfected with
pGL4.1–miR-146a–Luc and pcDNA3–Stat3, Stat3 S727A
pRc/CMV (Addgene, Watertown, MA), or pCDNA3-SIGIRR.
The thymidine kinase promoter–Renilla luciferase reporter
plasmid served as an internal control. At 48–72 hours after
transfection, luciferase and Renilla signals were measured
using a Dual-Luciferase Reporter Assay Kit (Promega) by
the CLARIO star multiplate reader (BMG Labtech, Ortenberg,
Germany).

Quantitative Real-Time PCR
Total RNA was isolated using TRIzol (ThermoFisher).
cDNA was synthesized using a high-capacity cDNA reversetranscription kit (Bio-Rad, Hercules, CA). For the quantiﬁcation of gene ampliﬁcation, real-time PCR was performed using
a ViiA7 or Quantstudio 3 (Applied Biosystems, Waltham, MA).
The sequences of gene-speciﬁc primers are available upon
request. 18S ribosomal RNA or glyceraldehyde-3-phosphate
dehydrogenase were used as endogenous normalization
control.

Western Blot Analysis
The Western blot analysis was performed as described
previously. In brief, cells were washed once with ice-cold
PBS and suspended in RIPA lysis buffer (Pierce, Waltham,
MA), added with a cocktail of protease inhibitors. Mouse
tissues in RIPA buffer containing protease and phosphatase
inhibitors were homogenized by bullet blender (Midwest
Scientiﬁc, St. Louis, MO). The concentration of the crude
protein was measured with a bicinchoninic acid Protein
Assay Kit (ThermoFisher Scientiﬁc). Equal amounts of cell
lysates were loaded and separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, and gels were
blotted to polyvinylidene diﬂuoride membranes. Membranes with blotted proteins were incubated with primary
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antibodies, washed, and incubated with peroxidase-conjugated secondary antibodies. Reactive proteins were shown
with an enhanced chemiluminescence detection system and
visualized on the imaging system iBright FL1000 (ThermoFisher). Densitometry was performed using ImageJ
software (National Institutes of Health, Bethesda, MD), and
changes were normalized to actin beta (ACTB) or the corresponding nonphosphorylated antibody.

Immunostaining
Parafﬁn sections of intestine were cut in 4-um thickness. Sections were deparafﬁnized with xylene and
graded series of alcohol. Antigen retrieval was performed
using citrate buffer for 20 minutes at 95 C. After several
rinses with PBS, sections were blocked with Power Block
Universal Blocking Reagent for 1 hour and then stained
overnight at 4 C with primary anti-SIGIRR (rabbit, 1:30;
MyBioSource, San Diego, CA) and anti-IRAK1 (rabbit,
1:100; Abcam, Cambridge, UK ). After washing with PBS,
slides were stained with secondary antibody conjugated
with Alexa488 (1:100; Invitrogen, Waltham, MA) for 1
hour at room temperature.
For frozen sections, freshly isolated intestine tissue was
ﬁxed in ice-cold 4% paraformaldehyde for 6 hours, rinsed
several times with ice-cold PBS, and then left overnight at
4 C in 30% sucrose. Tissue was embedded in optimal cutting temperature (OCT) compound and cryosectioned with
10-um thickness. Sections were washed several times with
PBS and blocked with Power Block (Biogenex Laboratories,
Fremont, CA) for 1 hour and then stained with primary antiStat3–phospo-S727 (rabbit, 1:100; Abcam) overnight at 4 C.
After washing with PBS, secondary antibody conjugated
with Alexa488 (1:100; Invitrogen) was added and kept for 1
hour at room temperature.
In both parafﬁn and frozen sections, after treating with
secondary antibodies the slides were washed several times
with PBS, counterstained with 40 60 -diamidino-2-phenylindole,
and mounted with FLUORO-GEL (1798510; Electron Microscopy Science, Hatﬁeld, PA). All primary and secondary
antibodies were diluted in Antibody Diluent Solution (Invitrogen). Images were acquired using 25/oil objective with
a Zeiss Inverted LSM 510 meta laser scanning confocal
microscope(Oberkochen, Germany). Red–green–blue images
were assembled using ImageJ software.

Protein Structure Construction
The sequence of SIGIRR (Uniprot Q6IA17; www.uniprot.
org/) was parsed into extracellular and intracellular parts
followed by modeling each with I-TASSER (https://
zhanggroup.org/I-TASSER/),42 joining the two with the
transmembrane helix, energy minimizing, and embedding
within a lipid membrane using the YASARA tools (http://
www.yasara.org/).43 The SIGIRR and MYD88 dimer model
was generated by merging the Toll-interleukin receptor
domain homology models from protein data bank (PDB)
ﬁles 1T3G. SIGIRR P115R 2-dimensional images were
generated by Phyre2.

Data Analysis
Data are presented as means ± SD or as the median with
interquartile range. P < .05 was considered signiﬁcant. For
cell culture experiments, data are from a minimum of 3
independent experiments with adequate technical replicates
used for quantiﬁcation. All animal data were obtained in
littermate controls. For animal experiments, a minimum of 4
animals were used for each experimental group. RNA
quantiﬁcation and PCR results had 2–3 technical replicates.
Statistical analysis was performed using GraphPad Prism
9.0 (San Diego, CA). For all data, we initially examined
whether distribution of data was Gaussian using the D’Agostino–Pearson omnibus normality test. Comparisons between 2 groups were made by a 1-sample, 2-tailed Student t
test for parametric or nonparametric data. Comparisons
between 3 or more groups were analyzed by 1-way analysis
of variance and post hoc Tukey tests for multiple
comparisons.
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